Novartis reports Q3 core EPS $2.46 vs. $2.25 last year
Novartis reported Q3 2026 core EPS of $2.46, up from $2.25 last year, with net sales reaching $14.5B, an increase from $13.9B. CEO Vas Narasimhan attributed growth to strong brand performance and productivity. The company upgraded its full-year guidance and highlighted pipeline advancements, including positive Phase III results for remibrutinib and EU submission for pelabresib. Despite a setback in del-desiran, progress continues in FSHD and DMD programs.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to drive short‑term price appreciation, while mixed trial results may introduce volatility.
Market read
First‑report earnings beat and guidance upgrade for a large‑cap pharma company, with potential sector‑wide ripple effects.
What to watch
Potential headwinds from the less‑than‑expected readout in DM1 and ongoing regulatory scrutiny could temper enthusiasm.
Background
Novartis highlighted solid sales growth, pipeline progress with Phase III data, and a mixed readout in DM1.
Ticker impact
Novartis reported Q3 net sales of $14.5B and core EPS of $2.46, beating prior year and upgrading full-year guidance.
likely upward pressure as investors price in higher guidance
The surprise EPS beat and guidance raise are fresh, material information for a large‑cap pharma stock.
Market effects
Boosts sentiment for the broader pharma/healthcare sector as earnings beat may lift peers.
Positive for European markets where Novartis is a major component.
Adds to global growth narrative for large‑cap biotech and pharma companies.
Counterpoint
If the guidance upgrade is modest, the market may have already priced it in, limiting upside.
Key entities
- ExecutiveVas Narasimhan
CEO of Novartis, provided commentary on earnings and pipeline.
